Overview Single-time-point (STP) dosimetry has emerged as a practical alternative to traditional multi-time-point approaches for radiopharmaceutical therapies. In metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 labelled PSMA (177Lu-PSMA), STP dosimetry at around 48 hours post-administration can reliably estimate absorbed doses to kidneys and tumors, reducing imaging burden and streamlining clinical workflows. Why STP Dosimetry…